128 related articles for article (PubMed ID: 3140572)
1. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo.
Hammarbäck S; Bäckström T
Acta Obstet Gynecol Scand; 1988; 67(2):159-66. PubMed ID: 3140572
[TBL] [Abstract][Full Text] [Related]
2. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.
Sundström I; Nyberg S; Bixo M; Hammarbäck S; Bäckström T
Acta Obstet Gynecol Scand; 1999 Nov; 78(10):891-9. PubMed ID: 10577620
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome.
Hammarbäck S; Ekholm UB; Bäckström T
Acta Endocrinol (Copenh); 1991 Aug; 125(2):132-7. PubMed ID: 1897330
[TBL] [Abstract][Full Text] [Related]
4. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome.
Nyberg S; Bäckström T; Zingmark E; Purdy RH; Poromaa IS
Gynecol Endocrinol; 2007 May; 23(5):257-66. PubMed ID: 17558683
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study.
Magos AL; Brincat M; Studd JW
Br Med J (Clin Res Ed); 1986 Jun; 292(6536):1629-33. PubMed ID: 3087550
[TBL] [Abstract][Full Text] [Related]
6. Relationship between symptom severity and hormone changes in women with premenstrual syndrome.
Hammarbäck S; Damber JE; Bäckström T
J Clin Endocrinol Metab; 1989 Jan; 68(1):125-30. PubMed ID: 2491857
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone.
Watson NR; Studd JW; Savvas M; Garnett T; Baber RJ
Lancet; 1989 Sep; 2(8665):730-2. PubMed ID: 2570971
[TBL] [Abstract][Full Text] [Related]
8. Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial.
Andersen AN; Larsen JF; Steenstrup OR; Svendstrup B; Nielsen J
Br J Obstet Gynaecol; 1977 May; 84(5):370-4. PubMed ID: 329858
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ovulation with oral progestins--effectiveness in premenstrual syndrome.
West CP
Eur J Obstet Gynecol Reprod Biol; 1990; 34(1-2):119-28. PubMed ID: 2303145
[TBL] [Abstract][Full Text] [Related]
10. Buserelin in premenstrual syndrome.
Hussain SY; Massil JH; Matta WH; Shaw RW; O'Brien PM
Gynecol Endocrinol; 1992 Mar; 6(1):57-64. PubMed ID: 1580169
[TBL] [Abstract][Full Text] [Related]
11. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes.
Bancroft J; Boyle H; Warner P; Fraser HM
Clin Endocrinol (Oxf); 1987 Aug; 27(2):171-82. PubMed ID: 3117452
[TBL] [Abstract][Full Text] [Related]
12. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
13. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome.
West CP; Hillier H
Hum Reprod; 1994 Jun; 9(6):1058-63. PubMed ID: 7962376
[TBL] [Abstract][Full Text] [Related]
14. The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study.
Leather AT; Studd JW; Watson NR; Holland EF
Gynecol Endocrinol; 1999 Feb; 13(1):48-55. PubMed ID: 10368798
[TBL] [Abstract][Full Text] [Related]
15. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.
Schmidt PJ; Nieman LK; Danaceau MA; Adams LF; Rubinow DR
N Engl J Med; 1998 Jan; 338(4):209-16. PubMed ID: 9435325
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
17. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
18. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial.
Smith S; Rinehart JS; Ruddock VE; Schiff I
Obstet Gynecol; 1987 Jul; 70(1):37-43. PubMed ID: 3299178
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.
Brown CS; Ling FW; Andersen RN; Farmer RG; Arheart KL
Obstet Gynecol; 1994 Nov; 84(5):779-86. PubMed ID: 7936512
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
Lanzone A; Fulghesu AM; Villa P; Guida C; Guido M; Nicoletti MC; Caruso A; Mancuso S
Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
